Sanofi is reorganising its business units from seven to five in a bid to streamline its operations and ensure the success of its ambitious product launch plans. The revamp is the first major ...

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

Sanofi has temporarily stopped distributing and selling its flu shots in China out of concerns of waning potency. A Sanofi spokesperson confirmed the halt to Fierce Pharma. Supplies of the French ...

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...

Sanofi is following several of its big pharma industry peers into radiopharmaceuticals, striking a deal for a clinical-stage therapy now in discussion for a regulatory submission as a treatment ...

Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up ...

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic spontaneous urticaria.

Also Read: Sanofi’s Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant. Preliminary analysis of liver safety was consistent with ...

But, in the GEMINI trials, tolebrutinib failed the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when it came to reducing relapses over up to 36 months. Trying to find the ...